NCT04848363

Brief Summary

Comparison of the effectiveness: Quadratus lumborum (QL) block by levobupivacaine with placebo.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 12, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 19, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

June 16, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2022

Completed
Last Updated

June 18, 2021

Status Verified

June 1, 2021

Enrollment Period

11 months

First QC Date

March 12, 2021

Last Update Submit

June 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • NRS (Numeric rating scale)

    NRS scale 0-10, "no pain"; 10, "worst pain imaginable"

    two hours after surgery

Secondary Outcomes (8)

  • The need for opioid analgesics during surgery

    on operations

  • The need for opioid analgesics for postoperative pain relief

    72 hours after surgery

  • The need for antiemetic drugs to relieve postoperative nausea and vomiting

    12 hours after the surgery

  • Occurrence of prolonged post-operative ileus

    first two weeks after surgery

  • Blood glucose level

    after induction into anesthesia, immediately after the end of the surgery, 12 hours after the surgery

  • +3 more secondary outcomes

Study Arms (2)

Study group

EXPERIMENTAL

patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.

Procedure: Quadratus lumborum block

Control group

PLACEBO COMPARATOR

patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.

Procedure: Quadratus lumborum block

Interventions

QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.

Control groupStudy group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who have undergone left-sided or right-sided laparoscopic hemicolectomy.
  • Patient's willingness and ability to sign an informed consent document

You may not qualify if:

  • Allergy to local anesthetics
  • Chronic pain syndrome and associated opioid use.
  • Coagulopathy
  • Uncontrolled diabetes mellitus
  • Physical Status Classification System scale above 3
  • Diseases associated with the pathology of the hypothalamus
  • Diseases associated with the pathology of the pituitary gland
  • Diseases associated with the pathology of the adrenal glands

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Petrovsky Research National Centre of Surgery ( Petrovsky NRCS)

Moscow, 119991, Russia

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Triple blindness. The Principal Investigator performing the blockade knows the randomization group. The anesthesiologist, postoperative pain assessor, and study participant do not know the randomization group.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Distribution: randomized Intervention model: parallel distribution 2 groups * Control group: patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. Before surgery will be performde bilateral blockade of the QL muscle with normal saline. * Study group: patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. The QL blockade will be performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor of the department of anesthesiology and resuscitation

Study Record Dates

First Submitted

March 12, 2021

First Posted

April 19, 2021

Study Start

June 16, 2021

Primary Completion

April 30, 2022

Study Completion

May 30, 2022

Last Updated

June 18, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

All patient data will be confidential

Locations